Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mesoporous polydopamine nanoparticles for tumor T1-T2 magnetic resonance imaging

A mesoporous polydopamine and nanoparticle technology, applied in the field of biomedical materials, can solve the problems of not having T1-T2 dual-mode imaging effect and limiting the application of tumor diagnosis and treatment, and achieve good photothermal conversion ability, accurate MRI results, good dispersion effect

Active Publication Date: 2021-05-07
SUN YAT SEN UNIV
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This anti-cancer diagnostic agent is prepared by encapsulating metal precursors without metal doping, but it does not have T1-T2 dual-modal imaging effects, which limits its application in the integration of tumor diagnosis and treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesoporous polydopamine nanoparticles for tumor T1-T2 magnetic resonance imaging
  • Mesoporous polydopamine nanoparticles for tumor T1-T2 magnetic resonance imaging
  • Mesoporous polydopamine nanoparticles for tumor T1-T2 magnetic resonance imaging

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 Preparation of manganese-mesoporous polydopamine nanoparticles by doping method before polymerization

[0052] (1) Dissolve 90 mg of dopamine hydrochloride and 3 mg of manganese sulfate hydrate in 3 mL of ultrapure water (the mass ratio of dopamine hydrochloride to manganese sulfate hydrate is 30:1; the mass-volume ratio of manganese sulfate hydrate to ultrapure water is 1 mg:1 mL) , Stir at 180rpm in the dark for 24h to obtain a manganese chelate-dopamine solution;

[0053] (2) the 0.3mL manganese chelation-dopamine solution of 36mg surfactant F127 and step (1) is joined in the mixed solution of 6mL ethanol and 6mL ultrapure water (the mass volume ratio of F127 and manganese chelation-dopamine solution is 120mg: 1mL, the volume ratio of ethanol, ultrapure water and manganese chelation-dopamine solution is 20:20:1), and stirred at 180rpm in the dark for 20min; figure 1 Shown in (1), manganese chelation-dopamine solution, F127 are dispersed in the mixed soluti...

Embodiment 2

[0057] Example 2 Preparation of manganese-mesoporous polydopamine nanoparticles by doping method before polymerization

[0058] (1) 99mg dopamine hydrochloride and 3mg manganese sulfate hydrate are dissolved in 3.75mL ultrapure water (the mass ratio of dopamine hydrochloride and manganese sulfate hydrate is 33:1; the mass volume ratio of manganese sulfate hydrate and ultrapure water is 1mg:1.25 mL), 150rpm avoid light and stir for 26h, obtain manganese chelation-dopamine solution;

[0059] (2) join the manganese chelation-dopamine solution of 30mg surfactant F127 and 0.3mL step (1) in the mixed solution of 4.8mL ethanol and 4.8mL ultrapure water (the mass volume of F127 and manganese chelation-dopamine solution Ratio is 100mg:1mL, the volume ratio of ethanol, ultrapure water and manganese chelation-dopamine solution is 20:20:1.25), 150rpm avoids light and stirs 25min;

[0060] (3) Add 0.3mL 1,3,5-trimethylbenzene (TMB) solution while shaking in a water bath ultrasonic (4kHz) ...

Embodiment 3

[0063] Example 3 Manganese-mesoporous polydopamine nanoparticles prepared by doping before polymerization

[0064] (1) 105mg dopamine hydrochloride and 3mg manganese sulfate hydrate are dissolved in 4.5mg ultrapure water (the mass ratio of dopamine hydrochloride and manganese sulfate hydrate is 35:1; the mass volume ratio of manganese sulfate hydrate and ultrapure water is 1mg:1.5 mL), and stirred at 200rpm in the dark for 22h to obtain manganese chelation-dopamine solution;

[0065] (2) join the 0.3mL manganese chelation-dopamine solution of 45mL surfactant F127 and step (1) in the mixed solution of 4mL ethanol and 4mL ultrapure water (the mass volume ratio of F127 and manganese chelation-dopamine solution is 150mg: 1mL, the volume ratio of ethanol, ultrapure water and manganese chelation-dopamine solution is 20:20:1.5), 150-200rpm dark stirring for 25min;

[0066] (3) Add 0.4mL 1,3,5-trimethylbenzene (TMB) solution while shaking in a water bath ultrasonic (4kHz) at 25°C, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Hydrated particle sizeaaaaaaaaaa
Specific surface areaaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of biomedical materials, particularly relates to mesoporous polydopamine (MPDA) nanoparticles for tumor T1-T2 magnetic resonance imaging, and aims to prepare mesoporous polydopamine nanoparticles which are internally doped with metal and have a T1-T2 bimodal imaging effect. The manganese-mesoporous polydopamine nanoparticles are prepared by taking dopamine hydrochloride and an Mn precursor as basic raw materials and taking F127 and TMB as templates, and the nanoparticles are polydopamine nanoparticles which are internally doped with metal manganese and have a mesoporous structure, and have tumor microenvironment responsiveness, good photothermal conversion capability and good photothermal stability; the nanoparticles have good biocompatibility, and can be used as a T1 contrast agent and a T2 contrast agent for magnetic resonance imaging of tumors at the same time.

Description

technical field [0001] The invention belongs to the technical field of biomedical materials, and in particular relates to a mesoporous polydopamine nanoparticle used for tumor T1-T2 magnetic resonance imaging. Background technique [0002] Magnetic resonance imaging (MRI) has attracted extensive attention due to its advantages of high temporal and spatial resolution, no limitation of penetration depth, and no radiation damage. Magnetic resonance contrast agents can enhance MRI signal by reducing the relaxation time of T1 or T2 water protons. T1 is called the longitudinal relaxation time, which is usually used to increase the visualization saturation and suppress the magnetic resonance signal intensity or imaging intensity. Since tissues usually have a long longitudinal relaxation time, T1-weighted images are suitable for observing adipose tissue or anatomical structures. T2 is called the transverse relaxation time, and the proton spin in the lesion usually has a longer rela...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C08G73/06C08J9/28A61K41/00A61K49/12A61K49/18A61P35/00C08L79/02
CPCC08G73/0672C08J9/286A61K49/126A61K49/1857A61K41/0052A61P35/00C08J2379/02
Inventor 曹众吴英健杨茜
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products